CA3249784A1 - FREEZE-DRIED COMPOSITIONS - Google Patents
FREEZE-DRIED COMPOSITIONSInfo
- Publication number
- CA3249784A1 CA3249784A1 CA3249784A CA3249784A CA3249784A1 CA 3249784 A1 CA3249784 A1 CA 3249784A1 CA 3249784 A CA3249784 A CA 3249784A CA 3249784 A CA3249784 A CA 3249784A CA 3249784 A1 CA3249784 A1 CA 3249784A1
- Authority
- CA
- Canada
- Prior art keywords
- aqueous composition
- pharmaceutically acceptable
- acceptable salt
- rilpivirine
- reconstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263333557P | 2022-04-22 | 2022-04-22 | |
| US63/333,557 | 2022-04-22 | ||
| EP22173920.4 | 2022-05-17 | ||
| EP22173920 | 2022-05-17 | ||
| PCT/EP2023/060686 WO2023203255A1 (en) | 2022-04-22 | 2023-04-24 | Freeze dried compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3249784A1 true CA3249784A1 (en) | 2023-10-26 |
Family
ID=86330122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3249784A Pending CA3249784A1 (en) | 2022-04-22 | 2023-04-24 | FREEZE-DRIED COMPOSITIONS |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250275967A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4511007A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025513501A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119403545A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3249784A1 (cg-RX-API-DMAC7.html) |
| TW (2) | TW202406551A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2023203257A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| EP2330213A1 (en) | 2003-03-05 | 2011-06-08 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| PT3366278T (pt) | 2006-06-23 | 2024-10-21 | Janssen Sciences Ireland Unlimited Co | Suspensões aquosas de tmc278 |
| BRPI0715113A2 (pt) * | 2006-07-26 | 2013-06-04 | Sandoz Ag Sandoz Sa Sandoz Ltd | formulaÇço de caspofungina |
| AR065720A1 (es) * | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. |
| GB2513060B (en) * | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| HRP20201241T1 (hr) * | 2011-04-15 | 2020-11-27 | Janssen Pharmaceutica N.V. | Nanosuspenzije lijeka osušene zamrzavanjem |
| WO2018013673A1 (en) * | 2016-07-13 | 2018-01-18 | Reform Biologics, Llc | Stabilizing excipients for therapeutic protein formulations |
| WO2022109555A1 (en) | 2020-11-17 | 2022-05-27 | Janssen Sciences Ireland Unlimited Company | Treatment or prevention of hiv infection |
-
2023
- 2023-04-24 WO PCT/EP2023/060688 patent/WO2023203257A1/en not_active Ceased
- 2023-04-24 JP JP2024562210A patent/JP2025513501A/ja active Pending
- 2023-04-24 TW TW112115224A patent/TW202406551A/zh unknown
- 2023-04-24 TW TW112115222A patent/TW202408580A/zh unknown
- 2023-04-24 EP EP23722287.2A patent/EP4511007A1/en active Pending
- 2023-04-24 CA CA3249784A patent/CA3249784A1/en active Pending
- 2023-04-24 US US18/858,037 patent/US20250275967A1/en active Pending
- 2023-04-24 CN CN202380048657.2A patent/CN119403545A/zh active Pending
- 2023-04-24 WO PCT/EP2023/060686 patent/WO2023203255A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4511007A1 (en) | 2025-02-26 |
| JP2025513501A (ja) | 2025-04-24 |
| WO2023203255A1 (en) | 2023-10-26 |
| CN119403545A (zh) | 2025-02-07 |
| WO2023203257A1 (en) | 2023-10-26 |
| US20250275967A1 (en) | 2025-09-04 |
| TW202408580A (zh) | 2024-03-01 |
| TW202406551A (zh) | 2024-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11389447B2 (en) | Aqueous suspensions of TMC278 | |
| JP4211965B2 (ja) | サブミクロンの9−ヒドロキシリスペリドン脂肪酸エステルの水性懸濁液 | |
| ES2891976T3 (es) | Formulaciones a largo plazo | |
| JP2016503030A (ja) | 医薬組成物 | |
| KR20230038521A (ko) | 장기 작용 제형 | |
| CN115776881A (zh) | 长效配制品 | |
| US12208166B2 (en) | Lyophilized formulations of tegavivint | |
| KR20230137312A (ko) | 다이페닐피라진 유도체를 포함하는 약제학적 조성물 | |
| US20250275967A1 (en) | Freeze dried compositions | |
| US20250268896A1 (en) | Liquid compositions | |
| WO2022109555A1 (en) | Treatment or prevention of hiv infection | |
| WO2024068693A1 (en) | Long-acting formulations | |
| EP4593834A1 (en) | Long-acting formulations | |
| KR101811314B1 (ko) | Hiv 감염의 치료 및 예방 | |
| TW202333725A (zh) | 溶出測試 | |
| WO2023214059A1 (en) | Diphenylpyrazine compounds as prodrugs | |
| CN118251210A (zh) | 溶出测试 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20241018 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241022 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241022 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241119 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20241121 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20241121 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250305 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250305 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250305 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260303 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260303 |